CAJ | 학술논문

目的：评价糖尿病足(DF)血管腔内治疗的近期临床疗效和安全性。方法2013年1~12月收治的40例(46条患肢) DF患者接受血管腔内治疗。观察患者术后的技术成功率和并发症发生率，分析患者术后1周、1个月、3个月和6个月的临床症状、踝肱指数(ABI)和累积通畅率。结果成功开通患肢43条，技术成功率为93.5%。9例(22.5%)患者出现并发症。40例患者均获随访。技术成功的患肢术后临床症状较术前明显改善；术后1周、1个月、3个月和6个月的平均ABI分别为(0.91±0.18)、(0.87±0.25)、(0.84±0.15)和(0.75±0.21)，与术前(0.31±0.21)比较差异均有统计学意义(P<0.05)。术后6个月的一期通畅率、辅助通畅率和二期通畅率分别为78.4、81.6%、88.3%。结论糖尿病足血管腔内治疗是可行、安全、有效的，但其长期疗效有待进一步观察。
목적：평개당뇨병족(DF)혈관강내치료적근기림상료효화안전성。방법2013년1~12월수치적40례(46조환지) DF환자접수혈관강내치료。관찰환자술후적기술성공솔화병발증발생솔，분석환자술후1주、1개월、3개월화6개월적림상증상、과굉지수(ABI)화루적통창솔。결과성공개통환지43조，기술성공솔위93.5%。9례(22.5%)환자출현병발증。40례환자균획수방。기술성공적환지술후림상증상교술전명현개선；술후1주、1개월、3개월화6개월적평균ABI분별위(0.91±0.18)、(0.87±0.25)、(0.84±0.15)화(0.75±0.21)，여술전(0.31±0.21)비교차이균유통계학의의(P<0.05)。술후6개월적일기통창솔、보조통창솔화이기통창솔분별위78.4、81.6%、88.3%。결론당뇨병족혈관강내치료시가행、안전、유효적，단기장기료효유대진일보관찰。
Objective To evaluate the short-term curative clinical efficacy and the safety of endovascular treatment in treating diabetic foot. Methods The endovascular treatments of 40 patients (46 limbs) with diabetic foot were retrospectively reviewed from Jan. 2013 to Dec. 2013. The rates of technical success and complication were evaluated. Postoperative clinical symptoms, ankle-brachial index (ABI) and cumulative primary patency rates were evaluated 1 week, 1, 3 and 6 months after operation. Results The initial technical success was 93.5%(43 lower limbs) with a complication rate as 22.5%(9 cases). All 40 patients were followed up. The clinical symptoms were re-lieved in patients after successful endovascular treatment. The average ABI was (0.91±0.18), (0.87±0.25), (0.84±0.15) and (0.75±0.21) 1 week, 1, 3, 6 months after operation, respectively, which were significantly higher than preoperative ABI (0.31±0.21), P<0.01. Six months after operation, the primary, assisted-primary, and secondary patency rates were 78.4, 81.6%and 88.3%, respectively. Conclusion The Endovascular treatment in diabetic foot is a feasible, safe and effective procedure. However, the long term outcome needs to be observed in the future.